• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

手术相关和非手术相关的双膦酸盐相关性颌骨坏死(BRONJ):意大利多中心研究的 567 例回顾性分析。

Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study.

机构信息

Department of Otolaryngological/Dental/Ophthalmological and Cervico-Facial Sciences, University of Parma, Parma, Italy.

出版信息

Oral Oncol. 2011 Mar;47(3):191-4. doi: 10.1016/j.oraloncology.2010.11.007. Epub 2011 Feb 2.

DOI:10.1016/j.oraloncology.2010.11.007
PMID:21292541
Abstract

Invasive local procedures are often reported in clinical history of patients suffering from Bisphosphonates-Related Osteonecrosis of the Jaws (BRONJ) but over 40% of spontaneous forms have been also described in literature. We compared age, gender, underlying bone disorders, bisphosphonate therapy, clinical features and surgical outcome of 205 cases (36.2%) of BRONJ non surgery-triggered (group 1) with 362 (63.8%) cases of surgery-triggered forms (group 2). Differences between group 1 and 2 were analysed using Mann-Whitney U and χ(2) tests. Statistical analysis was performed using STATA 8. Zoledronate was the most used type of bisphosphonate (63.4% versus 69.0%) and the mandible was the most frequently involved site (63.9% versus 63.4%) in both groups. BRONJ in group 1 was more frequently multicentric (9.3% versus 5%, p<0.05), had a lower clinical stage (45.9% versus 13.8% in stage 1, p<0.01) and had a better outcome after surgical therapy (improvement in 74.1% versus 58.6%, p<0.05). The high prevalence of non surgery-triggered forms of BRONJ should be considered by oncologists, haematologists and general physicians who are advised to inform their patients regarding the importance of preventive dental protocols to control the possible causes of osteonecrosis not related to dental invasive procedures.

摘要

患有 bisphosphonates-related osteonecrosis of the jaws (BRONJ) 的患者的临床病史中常报告有侵袭性局部操作,但文献中也描述了超过 40%的自发性形式。我们比较了 205 例(36.2%)非手术触发 BRONJ(第 1 组)和 362 例(63.8%)手术触发形式(第 2 组)的患者的年龄、性别、潜在骨疾病、双膦酸盐治疗、临床特征和手术结果。使用 Mann-Whitney U 和 χ(2)检验分析组 1 和 2 之间的差异。使用 STATA 8 进行统计分析。唑来膦酸盐是最常用的双膦酸盐类型(63.4%比 69.0%),下颌骨是最常受累的部位(63.9%比 63.4%)在两组中。第 1 组的 BRONJ 更常为多中心(9.3%比 5%,p<0.05),临床分期较低(第 1 期 45.9%比 13.8%,p<0.01),手术后治疗效果更好(改善 74.1%比 58.6%,p<0.05)。非手术触发形式的 BRONJ 高患病率应引起肿瘤学家、血液学家和普通内科医生的关注,建议他们告知患者有关预防牙科方案的重要性,以控制与牙科侵袭性操作无关的可能导致坏死的原因。

相似文献

1
Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study.手术相关和非手术相关的双膦酸盐相关性颌骨坏死(BRONJ):意大利多中心研究的 567 例回顾性分析。
Oral Oncol. 2011 Mar;47(3):191-4. doi: 10.1016/j.oraloncology.2010.11.007. Epub 2011 Feb 2.
2
Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: a retrospective multi-hospital-based study of 87 Italian cases.口服双膦酸盐治疗骨质疏松症导致的颌骨骨坏死:87 例意大利多医院回顾性研究。
Eur J Intern Med. 2013 Dec;24(8):784-90. doi: 10.1016/j.ejim.2013.05.011. Epub 2013 Jun 12.
3
Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.口服双膦酸盐作为颌骨双膦酸盐相关骨坏死的一个病因:临床发现、风险评估及预防策略。
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):35-43. doi: 10.1016/j.joms.2009.01.003.
4
The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.手术切除在双膦酸盐相关颌骨骨坏死治疗中的作用。
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):85-95. doi: 10.1016/j.joms.2009.01.006.
5
Bisphosphonate related osteonecrosis of the jaws: spontaneous or dental origin?双膦酸盐相关性颌骨骨坏死:自发性还是牙科源性?
Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Sep;116(3):287-92. doi: 10.1016/j.oooo.2013.05.005.
6
Dental extractions in patient treated with intravenous bisphosphonates and risk of osteonecrosis of jaws: presentation of a preventive protocol and case series.接受静脉注射双膦酸盐治疗患者的拔牙与颌骨坏死风险:预防性方案及病例系列报告
Minerva Stomatol. 2010 Nov-Dec;59(11-12):593-601.
7
Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients.双膦酸盐相关颌骨坏死:26例患者的临床特征、危险因素、管理及治疗结果
J Oral Maxillofac Surg. 2009 Sep;67(9):1904-13. doi: 10.1016/j.joms.2009.04.051.
8
Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder.与双膦酸盐治疗相关的颌骨坏死:一种严重的继发性疾病。
Bone. 2007 Apr;40(4):828-34. doi: 10.1016/j.bone.2006.11.023. Epub 2007 Jan 22.
9
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.静脉注射双膦酸盐相关颌骨坏死:骨闪烁显像作为早期指标
J Oral Maxillofac Surg. 2009 Jul;67(7):1363-72. doi: 10.1016/j.joms.2009.03.005.
10
A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.一项回顾性研究评估了 576 例接受静脉注射双膦酸盐的癌症患者颌骨坏死的频率和风险因素。
Am J Clin Oncol. 2012 Aug;35(4):386-92. doi: 10.1097/COC.0b013e3182155fcb.

引用本文的文献

1
Prevention of bisphosphonate-related osteonecrosis of the jaw with basic fibroblast growth factor: an experimental study in rats.碱性成纤维细胞生长因子预防双膦酸盐相关颌骨坏死的实验研究:大鼠实验
Odontology. 2025 Feb 20. doi: 10.1007/s10266-025-01073-w.
2
Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS.乳腺癌和前列腺癌患者CTIBL管理中的药物相关性骨坏死(MRONJ)。SIPMO和SIOMMMS联合报告
J Bone Oncol. 2024 Dec 16;50:100656. doi: 10.1016/j.jbo.2024.100656. eCollection 2025 Feb.
3
Oropharyngeal Adverse Events to Drugs and Vaccines: Pharmacovigilance Data From Italy (2019-2021).
药物和疫苗的口咽不良事件:来自意大利的药物警戒数据(2019 - 2021年)
Oral Dis. 2025 Mar;31(3):993-1005. doi: 10.1111/odi.15145. Epub 2024 Oct 6.
4
Piezoelectric Surgery, Er:YAG Laser Surgery and Nd:YAG Laser Photobiomodulation: A Combined Approach to Treat Medication-Related Osteonecrosis of the Jaws (MRONJ).压电外科、铒钇铝石榴石激光手术和钕钇铝石榴石激光光生物调节:治疗颌骨药物相关性骨坏死(MRONJ)的联合方法。
Dent J (Basel). 2024 Aug 19;12(8):261. doi: 10.3390/dj12080261.
5
Osteonecrosis of the Jaw Associated with Bisphosphonates Infusion for Treatment of Plasma Cell Myeloma-A Retrospective Observational Study of Northern Portuguese Population.双膦酸盐输注治疗浆细胞骨髓瘤相关颌骨骨坏死——葡萄牙北部人群的一项回顾性观察研究
J Clin Med. 2024 May 2;13(9):2679. doi: 10.3390/jcm13092679.
6
Role of Actinomyces spp. and related organisms in the development of medication-related osteonecrosis of the jaw (MRONJ): Clinical evidence based on a case series.放线菌属及相关微生物在药物性颌骨坏死(MRONJ)发生发展中的作用:基于病例系列的临床证据
Eur J Microbiol Immunol (Bp). 2023 Dec 1;13(4):125-134. doi: 10.1556/1886.2023.00041. Print 2023 Dec 21.
7
Drug holiday of high-dose denosumab and recovery from osteoclast inhibition using immunohistochemical investigation of 7 patients with medication-related osteonecrosis of the jaw undergoing segmental mandibulectomy.7例因药物相关性颌骨坏死接受下颌骨节段性切除术患者,采用免疫组化研究高剂量地诺单抗药物假期及破骨细胞抑制恢复情况。
J Dent Sci. 2023 Oct;18(4):1645-1650. doi: 10.1016/j.jds.2023.01.021. Epub 2023 Feb 11.
8
Prediction of medication-related osteonecrosis of the jaws using machine learning methods from polymorphisms and clinical information.利用多态性和临床信息通过机器学习方法预测颌骨药物相关性骨坏死
Front Med (Lausanne). 2023 Jun 21;10:1140620. doi: 10.3389/fmed.2023.1140620. eCollection 2023.
9
Macrophage miR-149-5p induction is a key driver and therapeutic target for BRONJ.巨噬细胞 miR-149-5p 的诱导是 BRONJ 的关键驱动因素和治疗靶点。
JCI Insight. 2022 Aug 22;7(16):e159865. doi: 10.1172/jci.insight.159865.
10
Relationship between drug holiday of the antiresorptive agents and surgical outcome of medication-related osteonecrosis of the jaw in osteoporosis patients.抗吸收药物的停药期与骨质疏松症患者药物相关性颌骨坏死的手术结果之间的关系。
Sci Rep. 2022 Jul 7;12(1):11545. doi: 10.1038/s41598-022-15720-7.